Science

About APAC

Mechanism of action

Aplagon’s proprietary APAC is a dual AntiPlatelet and AntiCoagulant (APAC) with unique antithrombotic and anti-inflammatory properties.
APAC (high negative charge) specifically targets arterial injury sites by binding to proteins (positive charge) which are exposed to blood. When targeting the vascular injury APAC acts locally to inhibit thrombosis and inflammation.

APAC improves blood circulation and the cross-talk between vasculature, coagulation and inflammation.

Targets vascular injury sites by binding to exposed von Willebrand factor and collagen under high blood flow conditions (arteries, microcirculation).

Preserves normal hemostasis by allowing platelet adhesion to the vascular injury sites to support healing and inhibit thromboinflammation.

Acts as a potent and selective antiplatelet and anticoagulant.

Inhibits inflammation via several mechanisms.

APAC can be administered for prevention or as a treatment:

Acts as a local antithrombotic with anti-inflammatory and anti-atherogenic properties; mode of vascular administration is flexible – local and/or systemic (intravenous). Protects from vascular inflammation and progression of atherosclerotic lesions, and subsequently supports vascular healing and prevents arterial occlusions.	By targeting the vascular injury sites, APAC can remodel/reprogram the vessel wall to support natural healing. Localized action and limited systemic exposure reduce bleeding risk versus current antithrombotic options.

APAC has the potential to be applied in a wide range of indications having thromboinflammation as an underlying cause:

Targets the arterial injury site, caused by disease or vascular surgery/interventions
Prevents occlusions by inhibiting thromboinflammation locally at the injury sites

Thromboinflammation is a key driver of most of the diseases associated with arterial thrombosis, i.e., occlusion to blood circulation.

Aplagon’s CSO and co-founder, Professor Riitta Lassila, talks about how APAC works.